Brenner, who has worked in the FDA’s Center for Devices and Radiological Health, will lead the agency until a permanent ...

RBC Capital Markets adjusted its stance on Intra-Cellular Therapies shares, downgrading the biopharmaceutical company from Outperform to Sector Perform. The firm, however, raised its price target on ...

With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be ...